View ValuationPredilife 将来の成長Future 基準チェック /06現在、 Predilifeの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Biotechs 収益成長58.0%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesNew Risk • May 11New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Negative equity (-€15m). Earnings have declined by 13% per year over the past 5 years. Revenue is less than US$1m (€728k revenue, or US$856k). Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Market cap is less than US$100m (€11.3m market cap, or US$13.2m).New Risk • Dec 18New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of French stocks, typically moving 6.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Negative equity (-€15m). Earnings have declined by 13% per year over the past 5 years. Revenue is less than US$1m (€728k revenue, or US$854k). Minor Risks Share price has been volatile over the past 3 months (6.9% average weekly change). Market cap is less than US$100m (€13.0m market cap, or US$15.2m).Reported Earnings • Oct 12First half 2025 earnings releasedFirst half 2025 results: Revenue: €392.8k (up 149% from 1H 2024). Net loss: €1.89m (loss narrowed 20% from 1H 2024).New Risk • Jul 21New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of French stocks, typically moving 6.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Negative equity (-€13m). Earnings have declined by 17% per year over the past 5 years. Revenue is less than US$1m (€493k revenue, or US$577k). Minor Risks Share price has been volatile over the past 3 months (6.7% average weekly change). Market cap is less than US$100m (€12.1m market cap, or US$14.2m).Reported Earnings • Jun 09Full year 2024 earnings released: €1.13 loss per share (vs €1.14 loss in FY 2023)Full year 2024 results: €1.13 loss per share. Revenue: €498.7k (up 57% from FY 2023). Net loss: €4.26m (loss widened 1.0% from FY 2023). Revenue is forecast to grow 52% p.a. on average during the next 2 years, compared to a 17% growth forecast for the Biotechs industry in France.お知らせ • May 20Predilife S.A., Annual General Meeting, Jun 23, 2025Predilife S.A., Annual General Meeting, Jun 23, 2025. Location: 1 rue royale bureaux de la colline, batiment b 9e etage, saint cloud FranceNew Risk • May 13New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Negative equity (-€3.5m). Earnings have declined by 16% per year over the past 5 years. Revenue is less than US$1m (€301k revenue, or US$334k). Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Market cap is less than US$100m (€14.0m market cap, or US$15.6m).New Risk • Jul 26New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.0% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€4.3m free cash flow). Share price has been highly volatile over the past 3 months (62% average weekly change). Negative equity (-€9.1m). Earnings have declined by 13% per year over the past 5 years. Revenue is less than US$1m (€318k revenue, or US$345k). Minor Risks Shareholders have been diluted in the past year (2.0% increase in shares outstanding). Market cap is less than US$100m (€22.7m market cap, or US$24.6m).New Risk • Apr 22New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Negative equity (-€2.7m). Earnings have declined by 15% per year over the past 5 years. Revenue is less than US$1m (€312k revenue, or US$332k). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Market cap is less than US$100m (€15.2m market cap, or US$16.2m).New Risk • Mar 07New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of French stocks, typically moving 8.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Negative equity (-€2.7m). Earnings have declined by 15% per year over the past 5 years. Revenue is less than US$1m (€312k revenue, or US$340k). Minor Risks Share price has been volatile over the past 3 months (8.1% average weekly change). Market cap is less than US$100m (€16.9m market cap, or US$18.4m).Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). Independent Director Ombline de Villèle was the last independent director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Reported Earnings • Apr 27Full year 2021 earnings releasedFull year 2021 results: Net loss: €3.41m (loss widened 52% from FY 2020).Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). Independent Director Ombline de Villèle was the last independent director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Reported Earnings • Sep 29Full year 2020 earnings released: €0.64 loss per share (vs €0.71 loss in FY 2019)Full year 2020 results: Net loss: €2.25m (loss widened 7.1% from FY 2019).Is New 90 Day High Low • Jan 11New 90-day low: €6.85The company is down 4.0% from its price of €7.10 on 13 October 2020. The French market is up 14% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 25% over the same period.Is New 90 Day High Low • Nov 06New 90-day high: €8.30The company is up 24% from its price of €6.70 on 07 August 2020. The French market is up 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 12% over the same period.Is New 90 Day High Low • Oct 15New 90-day high: €7.80The company is up 20% from its price of €6.50 on 17 July 2020. The French market is down 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 11% over the same period. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Predilife は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測ENXTPA:ALPRE - アナリストの将来予測と過去の財務データ ( )EUR Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数6/30/20251-4-3-3N/A3/31/20251-4-3-3N/A12/31/20240-4-4-4N/A9/30/20240-4N/AN/AN/A6/30/20240-5N/AN/AN/A3/31/20240-4N/AN/AN/A12/31/20230-4-4-4N/A9/30/20230-4N/AN/AN/A6/30/20230-4N/AN/AN/A3/31/20230-4N/AN/AN/A12/31/20220-4-3-3N/A9/30/20220-3N/AN/AN/A6/30/20220-3-3-3N/A3/31/20220-3-3-3N/A12/31/20210-3-4-4N/A9/30/20210-3-4-4N/A6/30/20210-3-4-4N/A3/31/20210-3-3-3N/A12/31/20200-2-2-2N/A9/30/20200-2-2-2N/A6/30/20200-2-1-1N/A3/31/20200-2-2-2N/A12/31/20190-2-2-2N/A9/30/20190-3-3-2N/A6/30/20190-3-3-3N/A3/31/20190-3N/A-2N/A12/31/20180-2N/A-2N/A9/30/20180-2N/AN/AN/A6/30/20180-1N/AN/AN/A3/31/20180-1N/AN/AN/A12/31/20170-2N/A-2N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: ALPREの予測収益成長が 貯蓄率 ( 2.5% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: ALPREの収益がFrench市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: ALPREの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: ALPREの収益がFrench市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: ALPREの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: ALPREの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/24 01:11終値2026/05/22 00:00収益2025/06/30年間収益2024/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Predilife S.A. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Jean-Pierre LozaIn Extenso Financement & Marché
New Risk • May 11New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Negative equity (-€15m). Earnings have declined by 13% per year over the past 5 years. Revenue is less than US$1m (€728k revenue, or US$856k). Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Market cap is less than US$100m (€11.3m market cap, or US$13.2m).
New Risk • Dec 18New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of French stocks, typically moving 6.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Negative equity (-€15m). Earnings have declined by 13% per year over the past 5 years. Revenue is less than US$1m (€728k revenue, or US$854k). Minor Risks Share price has been volatile over the past 3 months (6.9% average weekly change). Market cap is less than US$100m (€13.0m market cap, or US$15.2m).
Reported Earnings • Oct 12First half 2025 earnings releasedFirst half 2025 results: Revenue: €392.8k (up 149% from 1H 2024). Net loss: €1.89m (loss narrowed 20% from 1H 2024).
New Risk • Jul 21New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of French stocks, typically moving 6.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Negative equity (-€13m). Earnings have declined by 17% per year over the past 5 years. Revenue is less than US$1m (€493k revenue, or US$577k). Minor Risks Share price has been volatile over the past 3 months (6.7% average weekly change). Market cap is less than US$100m (€12.1m market cap, or US$14.2m).
Reported Earnings • Jun 09Full year 2024 earnings released: €1.13 loss per share (vs €1.14 loss in FY 2023)Full year 2024 results: €1.13 loss per share. Revenue: €498.7k (up 57% from FY 2023). Net loss: €4.26m (loss widened 1.0% from FY 2023). Revenue is forecast to grow 52% p.a. on average during the next 2 years, compared to a 17% growth forecast for the Biotechs industry in France.
お知らせ • May 20Predilife S.A., Annual General Meeting, Jun 23, 2025Predilife S.A., Annual General Meeting, Jun 23, 2025. Location: 1 rue royale bureaux de la colline, batiment b 9e etage, saint cloud France
New Risk • May 13New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Negative equity (-€3.5m). Earnings have declined by 16% per year over the past 5 years. Revenue is less than US$1m (€301k revenue, or US$334k). Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Market cap is less than US$100m (€14.0m market cap, or US$15.6m).
New Risk • Jul 26New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.0% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€4.3m free cash flow). Share price has been highly volatile over the past 3 months (62% average weekly change). Negative equity (-€9.1m). Earnings have declined by 13% per year over the past 5 years. Revenue is less than US$1m (€318k revenue, or US$345k). Minor Risks Shareholders have been diluted in the past year (2.0% increase in shares outstanding). Market cap is less than US$100m (€22.7m market cap, or US$24.6m).
New Risk • Apr 22New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Negative equity (-€2.7m). Earnings have declined by 15% per year over the past 5 years. Revenue is less than US$1m (€312k revenue, or US$332k). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Market cap is less than US$100m (€15.2m market cap, or US$16.2m).
New Risk • Mar 07New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of French stocks, typically moving 8.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Negative equity (-€2.7m). Earnings have declined by 15% per year over the past 5 years. Revenue is less than US$1m (€312k revenue, or US$340k). Minor Risks Share price has been volatile over the past 3 months (8.1% average weekly change). Market cap is less than US$100m (€16.9m market cap, or US$18.4m).
Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). Independent Director Ombline de Villèle was the last independent director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Reported Earnings • Apr 27Full year 2021 earnings releasedFull year 2021 results: Net loss: €3.41m (loss widened 52% from FY 2020).
Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). Independent Director Ombline de Villèle was the last independent director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Reported Earnings • Sep 29Full year 2020 earnings released: €0.64 loss per share (vs €0.71 loss in FY 2019)Full year 2020 results: Net loss: €2.25m (loss widened 7.1% from FY 2019).
Is New 90 Day High Low • Jan 11New 90-day low: €6.85The company is down 4.0% from its price of €7.10 on 13 October 2020. The French market is up 14% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 25% over the same period.
Is New 90 Day High Low • Nov 06New 90-day high: €8.30The company is up 24% from its price of €6.70 on 07 August 2020. The French market is up 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 12% over the same period.
Is New 90 Day High Low • Oct 15New 90-day high: €7.80The company is up 20% from its price of €6.50 on 17 July 2020. The French market is down 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 11% over the same period.